Literature DB >> 21793715

Distribution properties of lentiviral vectors administered into the striatum by convection-enhanced delivery.

Edward White1, Alison Bienemann, Lisa Megraw, Chotirote Bunnun, Marcella Wyatt, Hannah Taylor, Steven Gill.   

Abstract

Before the successful use of lentiviral vectors in clinical trials it is essential that strategies for direct vector delivery into the brain be evaluated in vivo, particularly as these vectors are significantly larger than the brain extracellular space. To date no such studies have been undertaken. In this study, convection-enhanced delivery (CED) was employed in an attempt to achieve widespread lentiviral delivery in the striatum. Infusions of equine infectious anemia virus (EIAV) and HIV vector constructs expressing the reporter gene β-galactosidase (β-Gal) were undertaken into the striatum at a range of flow rates and viral titers. In rats, all EIAV and HIV infusions led to the extensive transduction of cells in perivascular spaces throughout the brain. Although infusions were performed under standardized conditions, the number and volume of distribution of transduced cells were highly variable, with approximately one-third of EIAV infusions leading to no concentrated cell transduction in the striatum. Heparin coinfusion had no effect on EIAV distribution, although coinfusion of nimodipine resulted in a significant reduction in the number and volume of distribution of transduced cells. Intrastriatal EIAV delivery in pigs led to extensive transduction of mainly neurons, which could be effectively visualized in real time by T(2)-weighted magnetic resonance imaging. No infusions were associated with a significant inflammatory response. Therefore, despite its large size, lentiviral vectors can be administered by CED to the striatum in both small and large animal models. However, the variability in vector distribution under standardized conditions and widespread vector distribution through the perivascular spaces raise serious concerns regarding the practicality of lentivirus-mediated gene therapy in the brain in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793715     DOI: 10.1089/hum.2010.185

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  4 in total

Review 1.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 2.  Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates.

Authors:  Adriana Galvan; Michael J Caiola; Daniel L Albaugh
Journal:  J Neural Transm (Vienna)       Date:  2017-02-25       Impact factor: 3.575

3.  Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

Authors:  Kimberly P Kicielinski; E Antonio Chiocca; John S Yu; George M Gill; Matt Coffey; James M Markert
Journal:  Mol Ther       Date:  2014-02-20       Impact factor: 11.454

4.  Tackling obstacles for gene therapy targeting neurons: disrupting perineural nets with hyaluronidase improves transduction.

Authors:  Klaus Wanisch; Stjepana Kovac; Stephanie Schorge
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.